Ionis Pharmaceuticals (Nasdaq: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement with Bicycle Therapeutics (Nasdaq: BCYC) for tissue-targeted delivery of oligonucleotide therapeutics.
Bicycle is a UK-based biotech company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic pept (Bicycle) technology.
"Bicycles targeted to tumor antigens can rapidly and selectively deliver a variety of payloads into solid tumors"Ionis had an option for an exclusive license under the terms of a December 2020 evaluation and option agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze